Great Lakes Neuro Technologies (GLNT) funded by NIH for $1,743,051 with a Phase II SBIR grant, is launching commercialization and clinical studies to validate a system to continuously monitor dyskinesias associated with Parkinson’s disease (PD).
The technology will be developed and commercialized at GLNT with clinical validation studies to be completed at the University of Rochester, Johns Hopkins University, and Albany Medical College. (more…)